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Understanding how the host immune system signals in 
response to infection by pathogenic mycobacteria and 
how the bacteria activate immune evasion mecha-
nisms is central to the global efforts to thwart myco-
bacterial infections, primarily tuberculosis. Rapid 
advances in the field of cellular microbiology and 
comparative genomics together with powerful techni-
ques for studying the transcriptome and the proteome 
of the infected macrophage should aid in the under-
standing of the interplay between the host and the 
bacterium in its intracellular niche. This review sum-
marizes the present state of knowledge in this field. 
PATHOGENIC mycobacteria survive within the macrophage. 
Infections are acquired through inhalation of infective 
bacilli. Once in the lung, the mycobacteria are inter-
nalized by alveolar macrophages in which they replicate 
and set-up infection foci in the tissue of the alveolar wall. 
The local inflammatory response caused by phagocytosis 
of mycobacteria by alveolar macrophages leads to recruit-
ment of mononuclear cells from neighbouring blood cells 
and eventually formation of a granuloma which consists 
of a kernel of infected macrophages surrounded by foamy 
giant cells with lymphocytes delineating the periphery of 
the structure. The bacterium survives within the macro-
phage using a variety of mechanisms including inhibition 
of phagosome-lysosome fusion, inhibition of the acidifi-
cation of phagosomes and resistance to killing by oxy-
genated metabolites. The macrophage mounts its offence 
by producing an array of proinflammatory cytokines 
which trigger macrophage microbicidal activity1. On the 
other hand, the bacterium triggers processes to offset macro-
phage microbicidal activity and to create an environment 
favouring its own survival. In order to eventually design 
therapies whether chemotherapeutic or immun modula-
tory, it is necessary to identify the mechanisms by which 
the mycobacteria are phagocytosed, the mechanisms 
activated by the host to counter mycobacterial survival 
and the mechanisms by which the mycobacteria moderate 
the host immune response. The ability of Mycobacterium 
species to persist in their hosts depends on avoiding or 
minimizing the induction of a productive immune res-
ponse and suppressing the effector cascade once such a 
response has been developed. This review will focus on 
some aspects of the present state of knowledge of the 
innate immune response to mycobacteria and on how 
mycobacteria escape immune surveillance and survive 
within the macrophage. 
 Dendritic cells (DCs) play a crucial role in the immun  
response against bacterial pathogens. Immature DCs 
capture invading pathogens in the peripheral tissues and 
proc ss them into peptide fragments2. They then migrate 
to lymphoid tissues, undergo maturation and present the 
antigens on major histocompatibility complexes (MHCs), 
enabling activation of naïve T cells. Depending on the 
athogen recognized, naïve T cells can differentiate into 
T-help r-1 (Th1) cells (as in the case of pathogenic 
mycobacteria) which secrete interferon-g (IFN-g) or into 
T-helper 2 (Th2) cells which produce IL-4. IFN-g plays a 
central role in macrophage microbicidal activity. M. 
tuberculosis has developed molecular mechanisms to 
limit activation of macrophages by IFN-g3. The develop-
ment of Th1 T cells is driven by IL-12 which is produced 
by macrophages and dendritic cells following phagocyto-
sis of bacteria2,4. IL-12 is a crucial cytokine in controlling 
mycobacterial infection. IL-12 knockout mice are sus-
ceptible to M. tuberculosis infection5 and individuals 
with mutations in the genes for IL-12 or its receptor have 
increased susceptibility to mycobacterial infection6,7. 
Comparative analysis of gene expression responses in 
macrophages infected with M. tuberculosis also suggests 
that inhibition of IL-12 production is a key response by 
which this organism survives host defenses8. 
 Early interactions between lung dendritic cells (LDCs) 
and M. tuberculosis are thought to be critical for mount-
ing a protective, anti-mycobacterial immune response 
and for determining the outcome of the infection. M. 
tuberculosis enters human monocyte-derived dendritic 
cells after binding to the lectin DC-specific intercellular 
adhesion molecule-3 grabbing non-integrin (DC-SIGN)9. 
Whereas the complement receptor CR3 and mannose 
receptor (MR) are the main receptors for M. tuberculosis 
on macrophages10, DC-SIGN is critically important in 
d ndritic cells. Lipoarabinomannan (LAM) is the key 
ligand of DC-SIGN11. A brief overview of the role of 
LAM and other mycobacterial lipids in immunity is given  
below. e-mail: joyoti@vsnl.com 
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Role of LAM and other mycobacterial lipids in 
infection 
LAMs are one of the modulators of macrophage/dendritic 
cell functions. LAMs are lipoglycans restricted to the 
mycobacteria12. LAM has a tripartite structure composed 
of a carbohydrate backbone, a glycosylphosphatidyl ino-
sitol (GPI) anchor and capping motifs. The D-mannan 
core and the D-arabinan domain constitute the carbohy-
drate backbone. At its reducing end, the mannan core is 
terminated by the glycosyl-phosphatidylinositol anchor. 
The arabinan domain is capped either by mannosyl13–15 or 
phosphoinositide residues16,17. The Man-LAMs are chara-
cterized by the presence of mannosyl caps and are found 
in the slow-growing mycobacteria, M. tuberculosis, M. 
leprae and M. bovis BCG. The PI-LAMs contain phos-
phoinositide caps and are present in the fast-growing 
mycobacteria, e.g. M. smegmatis. 
 Binding of mannosylated LAM to immature DCs blocks 
both LPS-mediated maturation and IL-12 secretion18. 
Man-LAM binding to DC-SIGN interferes with DC matu-
ration signals and also induces IL-10 secretion19 thereby 
contributing to immune suppression. Targeting DC-SIGN 
is one of the strategies used by M. tuberculosis to escape 
immune surveillance20. Man-LAMs exert an anti-inflam-
matory effect attenuating LPS-induced tumour necrosis 
factor-a (TNF-a) and IL-12 p40 mRNA expression21. M. 
bovis BCG Man-LAM when added at the onset of mono-
cyte culture subsequently inhibits both IL-12 mRNA (p40 
and p30) expression and IL-12 p70 production by mature 
DCs22. Both manno-oligosaccharide caps and the GPI 
anchor fatty acid play a critical role in the inhibitory role 
of Man-LAM on IL-12 production23. 
 Man-LAMs activate the tyrosine phosphatase21 SHP-1. 
It is conceivable that Man-LAMs exert their antinflam-
matory functions by dephosphorylating kinases such as 
the mitogen-activated protein (MAP) kinases which are 
involved in TNF-a and IL-12 production. Accumulating 
evidence suggests that mycobacteria-infected macro-
phages undergo apoptosis24–26. Man-LAM is largely res-
ponsible for the inhibition of apoptosis in M. tuberculosis- 
infected macrophages. Man-LAM promotes Bad phos-
phorylation27. Bad is a proapoptotic member of the Bcl-2 
family that inhibits Bcl-XL function by sequestering it as 
a heterodimer28. Its phosphorylation dissociates it from 
the het rodimer and leads to its sequestration in the cyto-
sol in association with 14-3-3. Man-LAM is also able to 
prevent M. tuberculosis-induced calcium influx and to 
consequently inhibit calcium-dependent events associated 
with apoptosis29. Ca2+ participates in signal transduction 
and gene expression through the c-AMP-response ele-
ment binding protein (CREB) that is phosphorylated after 
Ca2+ influx30. c-AMP response element (CRE) is present 
in the promoter region of the TNF-a gene and CREB 
participates in IFN-g-dependent JAK/STAT signalling31 
also involved in apoptosis32. Man-LAM inhibits CREB 
function by inhibiting nuclear translocation of CREB29. 
Among the late events regulated by Man-LAM is the 
tilting of the TNF-a/IL-10 balance in favour of IL-10 
which is considered to be an antiapoptotic cytokine25. 
Man-LAM has recently been suggested to be crucial in 
pr vention of phagosomal maturation33. Some of the anti-
inflammatory and anti- poptotic signalling effects of 
Man-LAM are summarized in Figure 1. 
 Unlike Man-LAM, phosphatidylinositol dimannosides 
(PIM2) released by intracellular mycobacteria elicit the 
production of the proinflammatory cytokines TNF-a and 
monocyte chemoattractant protein 1 (MCP- ) which are 
both strong promoters of a granulom tous response34. 
 Genetic manipulations have helped in the understand-
ing of the requirement of unique mycobacterial lipids in 
infection. Phthiocerol mycocerosate (PDIM) is one such 
lipid. PDIM is a peripheral lipid which is essential for 
maintenance of infection in the lung tissue35,36. These 
lipids are shed into infected macrophages37, intercalate 
into the host cell membranes, are transported inside the 
cell and accumulate in a multivesicular lysosomal struc-
ture reminiscent of the MIIC compartment that is invol-
ved in antigen loading of MHC class II molecules. These 
vesicular structures are shed into the external medium 
through a constitutive exocytic process38. The e exoso-
mes induce a proinflammatory response comparable to 
that of intact bacilli and might function in vivo by 
expanding the influence of the bacterium beyond its host 
cell and helping in granuloma maintenance. 
 
 
Figure 1. Schematic representation of the anti-infl mmatory and 
anti-apoptotic effects of Man-LAM in macrophages. 
 
SPECIAL SECTION: TUBERCULOSIS 
CURRENT SCIENCE, VOL. 86, NO. 1, 10 JANUARY 2004 105
Toll receptor signalling 
The Toll-like receptor (TLR) proteins are key regulators 
of innate immune activation induced by M. tuberculo-
sis39. The engagement of the Toll-like receptor 4 (TLR4) 
and the IL-1 receptor initiates a common signalling 
pathway, leading to the sequential activation of the 
adapter protein MyD88, the IL-1 receptor kinases 
(IRAK), TNF receptor-associated factor-6 (TRAF6) and 
eventually the IkB kinase complex40. Recent studies have 
demonstrated that the novel proteins (Toll p)41 and 
TIRAP42,43 are likely to associate with the intracellular 
domains on the IL-1 receptor and/or TLR proteins. Addi-
tionally, TLR2 and TLR4 activate the signalling mole-
cule Akt44. Arabinose-capped LAM is a TLR2 agonist45. 
CD14 is likely to be necessary for activation of TLR2 by 
arabinose-capped LAM. The 19 kDa lipoprotein antigen 
of M. tuberculosis46 and the heat-stable protease-resistant 
soluble tuberculosis factor (STF)47 are both TLR2 
agonists. M. tuberculosis also demonstrates a cell-
associated, heat labile TLR4 agonist activity which con-
trasts with the secreted heat-stable TLR2 agonist STF. In 
contrast to M. tuberculosis, M. avium does not activate 
cells in a TLR4-dependent manner48. The 19 kDa lipo-
protein may play a role in NO-dependent antimicrobial 
activity in mouse macrophages49. However, how it func-
tions in human macrophages remains largely unknown. 
 TLR proteins are also linked to apoptosis. Whereas TLR2 
activation provides a proapoptotic signal50, blockade of 
TLR 4 eliminates almost all M. tuberculosis-induced 
human alveolar macrophage apoptosis51. Paradoxically, 
TLR proteins mediate both the suppre sion of antigen 
presentation and the induction of antimicrobial responses 
by macrophages. Stimulation of macrophages with M. 
tuberculosis 19 kDa antigen reduces MHC class II 
mRNA expression and surface expression in macro-
phages52,53. This altered expression of class II molecules 
correlates with decreased presentation of peptide antigens 
to T-lymphocyte hybridomas. Mycobacteria also have the 
ability to regulate TLR gene expression. M. avium infec-
tion of murine macrophages leads to increased TLR2 
mRNA and to the expression of TLR2 on the cell 
surface54. The question regarding the relative contribu-
tion of these receptors for containing M. tuberculosis 
infection in vivo has recently been addressed subjecting 
mice defective in CD14, TLR2 or TLR4 to low (100 
CFU) or high (2000 CFU) dose aerosol infection with M. 
tuberculosis. Granuloma formation, macrophage activation 
and secretion of proinflammatory cytokines in response 
to low-dose aerosol infection were identical in mutant 
and control mice55. However, high-dose aerosol chal-
lenge with 2000 CFU M. tuberculosis revealed TLR2 but 
not TLR4-defective mice to be more susceptible than 
normal mice. The function of the TLRs and CD14 in 
initiating protective responses against naturally low-dose 
airborne infection is therefore redundant. A single defi-
ciency in a pattern recognition receptor does not impair 
innate resistance to M. tuberculosis. However, macro-
phages from TLR2–/– show significantly decreased IL-12
p 40 levels. 
 
Mitog n activated protein kinase signalling 
The mitogen activated-protein (MAP) kinases are dual 
specificity kinases. In macrophages these are activated 
upon the binding of growth factors and inflammatory 
cytokines to specific receptors, and are important in the 
activation of cytokine gene trascription. The MAP kinase 
family is composed of the ERK1/2, p38 and SAPK/JNK 
pathways. There is considerable co-operation between 
these kinases56. The MAP kinases are activated by 
upstream MAPK kinases through a Thr-x-x-x-Tyr 
phosphorylation motif57. The activated MAPKs are 
responsible for phosphorylating and activating numerous 
transcription factors which function to stimulate the 
synthesis of various proinflammatory cytokines such as 
TNF-a, IL-1b and IL-6. The MAPKs are also involved in 
transcriptional regulation of NOS2 and cyclooxygenase58 
2. Recent studies have thrown light on the link between 
macrophage MAPK activation and mycobacterial in-
fection. ERK1/2 activation induces induction of the 
NOS2 gene following macrophage cell line stimulation 
with both Man-LAM and IFN-g59. Work by Reiner and 
colleagues with the human monocytic cell line THP-1 
suggests that Man-LAM limits macrophage activation by 
reducing ERK1/2 phosphorylation21.Work with both 
human60 and murine61 macrophages supports the view that 
TNF-a secretion from macrophages challenged with M. 
avium is dependent on MEK1 and ERK1/2 activation. 
Activation of MAPK pathways in both human and 
urine macrophages suggests that these pathways 
contribute to the virulence of the mycobacterial pathogen. 
Murine macrophages infected with virulent M. avium 
ex ibit early activation of p38 MAPK and ERK1/2 but 
this activation is quickly lost. In contrast, macrophages 
infected with non-pathogenic mycobacteria show sustained 
a tivation of MAP kinases62. There appears to be a reve se 
correlation between the pathogenicity of a mycobacterial 
species or strain and its ability to induce sustained 
activation of MAP kinases. Tse et al.63 have shown that 
synthesis of the macrophage deactivating agent prosta-
glandin E2 by M. avium-infected macrophages is dependent 
on p38 MAPK and its production results in increased 
virule c  of the Sm T morphotype. Much still needs to be 
elucidated regarding the upstream events regulating 
MAPK activation by pathogenic mycobacteria. Ca2+ is a 
potential upstream modulator. Infection with dead but not 
live M. tuberculosis results in a transient Ca2+ flux within 
macrophages64. Calcium efflux triggered by M. bovis 
induces interleukin 8 secretion from human monocytes65. 
The relationship betw en Ca2+ flux and MAPK signalling 
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has not yet been studied. There is still little information 
available on the transcription factors activated down-
stream of the MAP kinases. NF-IL-6 has been reported to 
control aerosolized M. tuberculosis infection in mice66. 
AP-1 is activated in macrophages treated with manno-
sylated phosphatidylinositol (PIM) from M. tuberculosis 
through TLR2 signalling67. 
Macrophage apoptosis triggered by mycobacteria 
Macrophages infected with mycobacteria undergo apop-
tosis. Host macrophage apoptosis represents an innate 
defense mechanism linked to killing of intracellular 
mycobacteria68,69. Macrophages infected either with an 
attenuated (H37Ra) or with a virulent strain of M. 
tuberculosis undergo apoptotic death when exposed to 
TNF-a or FasL, accompanied by a reduction in bacillary 
viability70. Monocytic THP-1 cell apoptosis in response 
to M. tuberculosis nfection involves caspases71 9 and 3. 
M. avium-mediated apopt sis of murine J774.1 macro- 
phages involves casp ses 8, 9 and 3 and is critically 
dependent on apopotosis signal-regulating kinase (ASK)1 
and p38 MAPK72. This signaling pathway is summarized 
in Figure 2. 
 Evasion of apoptosis by virulent mycobacteria has been 
demo strated73. Duan et al.74 suggest that increased Ca2+ 
flux into M. tuberculosis-infected macrophages leads to 
low levels of caspase activation and diminished mito-
cho drial cytochrome c release, hallmarks of apoptosis74. 
 It appears possible that virulent mycobacteria may 
avoid apoptosis by regulating the multimeric death induc-
ing signal complex (DISC). The possible mechanisms of 
death signalling in mycobacteria-infected macrophages 
and the mechanisms whereby death receptor signals are 
blocked will be the obvious focus of future studies. 
 
Manipulation of phagosome maturation by 
pathogenic mycobacteria 
Mycobacteria successfully parasitize the macrophage using 
a number of strategies to manipulate the phagosome (where 
they reside) and prevent its maturation. Bacteria-con-
taining vacuoles interact with endosomes and remain 
arrested in what could be described as a transitional state 
in phagosome biogenesis75,76. Bacteria-containing vacuo-
les are less acidic than their neighbouring lysosomes77 
probably due to the paucity of vacuolar ATPases78. Dur-
ing phagosome matur tion, phagosomes interact with the 
endosomal network and acquire markers found on early 
endosomes. Markers such as early endosomal antigen 1 
(EEA1) and the small GTPases of the Rab family are 
present on certain organelles and take part in specific 
fusion events. Rab5 dissociates from these vesicles as 
they acquire Rab7, another GTPase that function during 
fusion of the endosomes and lysosomes. On the other 
hand Rab5 is associated with, and retained by, phago-
somes containing live M. bovis BCG or M. tuberculo-
sis79,80. Recent reports have shown the association of the 
macrophage 32– 5 kDa galactose-binding lectin galectin 
(gal-3) with live Mycobacterium-containing phagosomes81. 
Live mycobacteria also have the ability to inhibit the 
increase in cytosolic Ca2+ concentration normally caused 
by phagocytosis64,82. Treatment of infected cells with the 
calcium ionophore A23178 causes an increase in [Ca2+]c 
reducing bacterial viability64, and correlating with an 
increase in calcium/calmodulin- ependent protein kinase 
(CaMKII) localization to the cytosolic face of these 
vacuoles. Recent studies suggest that M. uberculosis blocks 
Ca2+ signalling and phagosome maturation in human 
macrophages via inhibition of sphingosine kinase83. 
 Work from the group of Jan Pieters has argued in favour 
of a role of TACO or coronin 1 which is associated with 
the mycobacterial phagosome in prevention of vacuole 
maturation84 and suggests that sequestration of choles-
terol in Mycobacterium-containing vacuoles could be 
associated with retention of coronin 1 on the vacuolar 
membrane85. The specificity of the binding of Mycobac-
terium to cholesterol is still a matter of debate. Mycobac-
terial vacuoles are dynamic, fusion-competent vesicles86. 
 
 
Figure 2. Schematic representation of mycobacteria-induced ASK 1-
and caspase 8-dependent cell death in macrophages. 
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As of now how bacilli-containing vacuoles are retained in 
the early endosomal network remains incompletely under-
stood, particularly in terms of the critical bacterial effec-
tor molecules involved in this process. 
 
Antigen processing and presentation 
Infected macrophages or bystander antigen-presenting cells 
signal the presence of the pathogen through display of the 
pathogen-derived molecules in the context of MHC 
(mouse) or HLA (human) antigens. Class II antigens pre-
sent peptides generated within the endosomal-lysoso al 
continuum of the host cell for T cell recognition. These 
are relevant for vacuolar pathogens such as M. tuberculo-
sis. Newly synthesized MHC-II molecules associate with 
invariant chain in the endoplasmic reticulum and are 
transported via the trans-Golgi network to the endocytic 
pathway. Invariant chain is degraded by endosomal/lyso-
somal proteases, leaving the MHC–II molecules associa-
ted with class-II associated invariant chain peptide 
(CLIP). The MHC class II molecule is primed for antigen 
sampling by another chaperone, H2-M (mouse) or HLA-
DM (human) which removes CLIP and renders the 
antigen-combining cleft accessible. Once the MHC class II 
molecule is loaded, it is transported to the cell surface 
where the class II molecule, together with other co-
stimulatory molecules, is free to combine with the T cell 
receptor. Mycobacteria in resting macrophages sequester 
their vacuoles away from the normal antigen processing 
and presentation machinery of their host cell87. Infected 
macrophages also downregulate expression of both class II 
and co-stimulatory molecules88–91. Whether inhibition of 
JAK -mediated phosphorylation of STATI is involved in 
this or not, is still a matter of debate92. 
 Differential receptor usage by M. tuberculosis on DCs 
and macrophages may account for the different survival 
ability and trafficking pattern of mycobacteria in the two 
cell types93,94. DC-SIGN is present in M. tuberculosis 
vacuoles during the early steps of bacterial uptake, and is 
then rapidly expelled from the phagosome possibly as a 
result of recycling to the plasma membrane. DC-SIGN
could potentially carry mycobacterial glycolipids from 
the bacterial vacuole to the cell plasma membrane and/or 
to various subcellular compartments where glycolipids 
could be loaded onto CD1 molecules for presentation to 
CD1-resistant lymphocytes95. 
 In spite of recent advances in our understanding of 
mycobacteria–host interactions, there are many areas in 
which knowledge needs to be generated. The critical 
mycobacterial components that are important in virulence 
are not yet understood. The macrophage receptors that 
initiate the intracellular signalling pathways are not known.
Finally, studies carried out with M. avium need to be 
extended to M. tuberculosis. How mycobacteria signal 
the expression of molecules which influence survival or 
clearance has been most elegantly studied in the case of 
macrophages exposed to M. avium or its cell wall LAM. 
Th  arly innate response was analysed in cDNA exp-
ression arrays. Within 2 h the proinflammatory response 
included expression of genes encoding cytokines TNF-a, 
IL-8, IL-1 and adhesion molecules96. The proinflamma-
tory response subsided within 24 . After four days, when 
some bacteria were being degraded, others escaped 
destruction to replicate within intracellular vacuoles. In-
ducible NOS was not up-regulated and increased trans-
ferrin receptors could possibly facilitate mycobacterial 
growth. Sustained adhesion molecule and chemokine 
expression along with the formation of multinucleated 
giant cells appeared consistent with in vivo events. Thus 
macrophages appeared to be insufficiently microbicidal 
and to provide a non-h stile environment. Similar studies 
need to be performed in detail with M. tuberculosis. 
 Despite the knowledge generated in recent years, the 
control of mycobacterial infection through development 
of innovative therapies requires a more detailed under-
standing of the cellular processes controlling the survival 
of the bacterium within its host, particularly in relation to 
the key pathways linked to persistence. Development of 
uitable models of persistence should aid in this endea-
vour. As powerful techniques of proteomics emerge in 
which increasingly smaller amount of proteins can be 
s parated and analysed, these tools should provide a 
better understanding of the life of the mycobacterium 
within its intracellular niche, particularly in relation to 
pathogen-containing vacuole biogenesis and its arrest. 
 
1. Flynn, J. L. and Chan, J., Immunology of tuberculosis. Annu. Rev. 
Immunol., 2001, 19, 93–129. 
2. Banchereau, J. and Steinman, R. M., Dendritic cells and the 
control of immunity. Nature, 1998, 392, 245–252. 
3. Ting, L. M., Kim, A. C., Cattamanchi, A. and Ernst, J. D., Myco-
bacterium tuberculosis inhibits IFN-g transcriptional responses 
without inhibiting activation of STAT1. J . Immunol., 1999, 163, 
3898–3906. 
4. Trinchieri, G., Interleukin-12: a cytokine at the interface of in-
flammation and immunity. Adv Immunol., 1998, 70, 83–243. 
5. Cooper, A. M., Magram, J. Ferrante, J. and Orme, I. M., Inter-
leukin 12 (IL-12) is crucial to the development of protective 
immunity in mice intravenously infected with Mycobacterium 
tuberculosis. J . Exp. Med., 1997, 186, 39–45. 
6. Doffinger, R., Altare, F. and Casanova, J. L., Genetic heterogeneity 
of Mendelian susceptibility to mycobacterial infection. Microbes 
I fect., 2000, 2, 1553–1557. 
7. Altare, F., Jouanguy, E., Lamhamedi, S., Doffinger, R., Fischer, 
A. and Casanova, J. L., Mendelian susceptibility to mycobacterial 
infection in man. Curr. Opin. Immunol., 1998, 10, 413–417. 
8. Nau, G. J., Richmond, J. F. L., Schlesinger, A., Jennings, E. G., 
Lander, E. S. and Young, R. A., Human macrophage activation 
programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. 
USA, 2002, 99, 1503–1508. 
9. Tailleux, et al., DC-SIGN is the major Mycobacterium tubercu-
losis receptor on human dendritic cells. J . Exp. Med., 2003, 197, 
121–127. 
10. Schlesinger, L. Z., Macrophage phagocytosis of virulent but not 
attenuated strains of Mycobacterium tuberculosis is mediated by 
SPECIAL SECTION: TUBERCULOSIS 
CURRENT SCIENCE, VOL. 86, NO. 1, 10 JANUARY 2004 108
mannose receptors in addition to complement receptors. J . 
Immunol., 1993, 150, 2920–2930. 
11. Maeda, N. et al., The cell surface receptor DC-SIGN discriminates 
between Mycobacterium species through selective recognition of 
the mannose caps on lipoarabinomannan. J . Biol. Chem., 2003, 
278, 5513–5516. 
12. Chatterjee, D. and Khoo, K. H., Structural features of lipoarabino-
mannan from Mycobacterium bovis BCG: Determination of mle-
cular mass by laser desorption mass spectrometry. Glycobiology, 
1998, 8, 113–120. 
13. Venisse, A., Berjeaud, J. M., Chaurand, P., Gilleron, M. and Puzo, 
G., Structural features of lip arabinomannan from Mycobacterium 
bovis BCG: Determination of molecular mass by laser desorption 
mass spectrometry. J  Biol. Chem., 1993, 268, 12401–12411. 
14. Chatterjee, D., Khoo, K. H., McNeil, M. R., Dell, A., Morris, H. R. 
and Brennan, P. J., Structural definition of the non-reducing 
termini of mannose-capped LAM from Mycobacterium tuberculo-
sis through selective enzymatic degradation and fast atom bom-
bardment-mass spectrometry. Gl cobiology, 1993, 3, 497–500. 
15. Prinzis, S., Chatterjee, D. and Brennan, P. J., Structure and anti-
genicity of lipoarabinomannan from Mycobacterium bovis BCG. 
Gen. Microbiol., 1993, 139, 2649–2658. 
16. Gilleron, M., Himoudi, N., Adam, O., Constant, P., Venisse, A., 
Riviere, M. and Puzo, G., Mycobacterium smegmatis phospho-
inositols-glyceroarabinomannans. Structure and localization of 
alkali-labile and alkali-stable phosphoinositides. J . Biol. Chem., 
1997, 272, 117–124. 
17. Khoo, K. H., Dell, A., Morris, H. R., Brennan, P. J. and Chatterjee, 
D., Inositol phosphate capping of the nonreducing termini of 
lipoarabinomannan from rapidly growing strains of Mycobac-
terium. J . Biol. Chem., 1995, 270, 12380–12389. 
18. Nigou, J., Zelle, Rieser, C., Gilleron, M., Thurnher, M. and Puzo, 
G., Mannosylated lipoarabinomannans inhibit IL-12 production by 
human dendritic cells: evidence for a negative signal delivered 
through the mannose receptor. J . Immunol., 2001, 166, 7477–7485. 
19. Geijtenbeek, T. B., Van Vliet, S. J., Koppel, E. A., Sanchez-
Hernandez, M., Vanden-Broucke-Grauls, C. M., Appelmelk, B. 
and van Kooyk, Y., Mycobacteria target DC-SIGN to suppress 
dendritic cell function. J . Exp. Med., 2003, 197, 7–17. 
20. van Kooyk, Y., Appelmelk, B. and Geijtenbeek, T. B. H., A fatal 
attraction: Mycobacterium tuberculosis and HIV-1 target DC-SIGN 
to escape immune surveillance. Trends Mol. Med., 2003, 9, 153–159. 
21. Knutson, K. L., Hmama, Z., Herrea-Velit, P., Rochford, R. and 
Reiner, N. E., Lipoarabinomannan of Myc bacterium tuberculosis 
promotes protein tyrosine dephosphorylation and inhibition of 
mitogen-activated protein kinase in human mononuclear phago-
cytes. Role of the Src homology 2 containing tyrosine phosphatase 1. 
J . Biol. Chem., 1998, 273, 645–652. 
22. Johansson, U., Ivanyi, J. and Londei, M., Inhibition of IL-12 pro-
duction in human dendritic cells matured in the presence of 
Bacillus Calmette-Guerin or lipoarabinomannan. Immunol. Lett., 
2001, 77, 63–66. 
23. Nigou, J., Gilleron, M., Brando, T., Vercellone, A. and Puzo, G., 
Structural definition of arabinomannans from Myc bacterium 
bovis BCG. Glycoconj. J ., 1999, 16, 257–264. 
24. Rojas, M., Barrera, L. F. and Garcia, L. F., Induction of apoptosis in 
murine macrophages by Mycobacterium tuberculosis is reactive 
oxygen intermediates-independent. Biochem. Biophys. Res. Commun., 
1998, 247, 436–442. 
25. Rojas, M., Olivier, M., Gras, P., Barrera, L. F., Puzo, G. and 
Garcia, L. F., TNF-a and IL-10 modulate the induction of apoptosis 
by virulent Mycobacterium tuberculosis in murine macrophages. 
J . Immunol., 1999, 162, 6122–6131. 
26. Rojas, M., Barrera, L. F., Puzo, G. and Garcia, L. F., Differential 
induction of apoptosis by virulent Mycobacterium tuberculosis in 
resistant and susceptible murine macrophages: role of nitric oxide 
and mycobacterial products. J . Immunol., 1997, 159, 1352–1361. 
27. Maiti, D., Bhattacharyya, A. and Basu, J., Lipoarabinomanna  from 
Mycobacterium tuberculosis promotes macrophage survival by 
phosphorylating Bad through a phosphatidylinositol 3-kinase/Akt 
pathway. J Biol. Chem., 2001, 276, 329–333. 
28. Datta, S. R., Brunet, A. and Greenberg, M. E., Cellular survival: a 
play in three Akts. Genes Dev., 1999, 13, 2905–2927. 
29. Rojas, M., Garcia, L. F., Nigou, J., Puzo, G. and Oliver, M., Manno-
sylated lipoarabinomannan antagonizes Mycobacterium tuberculo-
sis-induced macrophage apoptosis by altering Ca2+-dependent cell 
signaling. J . Infect. Dis., 2000, 181, 240–251. 
30. P ser, S. and Storm, D. R., Role of Ca2+-stimulated adenylyl cycla-
ses in LTP and memory formation. Int. J . Dev. Eurosci., 2001, 19, 
387–394. 
31. Horvai, A. E. et al., Nuclear integration of JAK/STAT and Ras/ 
AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. USA, 
1997, 94, 1074–1079. 
32. Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A. and Fu, X. Y., 
Activation of the STAT signaling pathway can cause expression of 
caspase 1 and apoptosis. Mol. Cell. Biol., 1997, 17, 5328–5337. 
33. Fratti, R. A., Chaua, J., Vergne, I. and Deretic, V., Mycobacterium 
tuberculosis glycosylated phosphatidylinositol causes phagosome 
maturation arrest. Proc. Natl. Acad. Sci. USA, 2003, 100, 5437– 
5442. 
34. Rhoades, E., Hsu, F.-F., Torrelles, J. B., Turk, J., Chatterjee, D. 
and Russell, D. G., Identification and macrophage-activ ting acti-
vity of glycolipids released from intracellular Mycobacterium 
bovis BCG. Mol. Microbiol., 2003, 48, 875–888. 
35. Camacho, L. R., Ensergueix, D., Perez, E., Gicquel, B. and 
Guilhot, C., Identification of a virulence gene cluster of Mycobac-
terium tuberculosis by signature-tagged transposon mutagenesis. 
Mol. Microbiol., 1999, 34, 257–267. 
36. Cox, J. S., Chen, B., McNeil, M. and Jacobs, W. R., Complex lipid 
determines tissue- p cific replication of Mycobacterium tubercu-
losis in mice. Nature, 1999, 402, 79–83. 
37. Beatty, W. B., Rhoades, E. R., Ullrich, H. J., Chatterjee, D. and 
Russell, D. G., Trafficking and release of mycobacterial lipids 
from infected macrophages. Traffic, 2000, 1, 235–247. 
38. Beatty, W. L., Ullrich, H. J. and Russell, D. G., Mycobacterial 
surface moieties are released from infected macrophages by a 
consti utive exocytic event. Eur. J . Cell Biol., 2001, 80, 31–40. 
39. Heldwein, K. A. and Fenton, M., The role of Toll-like receptors in 
immunity against mycobacterial infection. Mi r bes. Infect., 2002, 
4, 937–944. 
40. Takeda, K. and Akira, S., Toll receptors and pathogen resistance. 
Cell. Microbiol., 2003, 5, 143–153. 
41. Bulut, Y., Faure, E., Thomas, L., Equils, O. and Arditi, M., 
Cooperation of Toll-like receptor 2 and 6 for cellular activation by 
soluble tuberculosis factor and Borrelia burgdorferi outer surface 
protein A lipoprotein: role of Toll-interacting protein and IL-1
receptor signaling molecules in Toll-like receptor 2 signaling. J . 
Immunol., 2001, 167, 987–994. 
42. Fitzgerald, K. A. et al., Mal (MyD88-adapter-like) is required for 
Toll-like receptor-4 signal transduction. Nature, 2001, 413, 78–83. 
43. Horng, T., Barton, G. M. and Medzhitov, R., TIRAP: an adapter 
molecule in the Toll signaling pathway. Nature Immunol., 2001, 2, 
835–841. 
44. Jones, B. W., Heldwein, K. A., Means, T. K., Saukoven, S. and 
Fenton, M. J., Differential roles of Toll-like receptors in the 
elicitation of proinflammatory responses by macrophages. Ann. 
Rheum. Dis., 2001, 60, Suppl. 3: iii, 6–12. 
45. Means, T. K., Lien, E., Yoshimura, A., Wang, S., Golenbock, D. 
T. and Fenton, M. J., The CD14 ligands lipoarabinomannan and 
lipopolysaccharide differ in their requirement for Toll-like recep-
tors. J . Immunol., 1999a, 163, 6748–6755. 
46. Brightbill, H. D. et al., Host defense mechanisms triggered by 
microbial lipoproteins through toll-like receptors. Science, 1999, 
285, 732–736. 
SPECIAL SECTION: TUBERCULOSIS 
CURRENT SCIENCE, VOL. 86, NO. 1, 10 JANUARY 2004 109
47. Means, T. K., Wang, S., Lien, E., Yoshimura, A., Golenbock, D. T. 
and Fenton, M. J., Human toll-like receptors mediate cellular acti-
vation by Mycobacterium tuberculosis. J . Immunol., 1999b, 163, 
3920–3927. 
48. Lien, E. et al., Toll-like receptor 2 functions as a pattern recogni-
tion receptor for diverse bacterial products. J . Biol. Chem., 1999, 
274, 33419–33425. 
49. Thoma-Uszynki, S. et al., Induction of direct antimicrobial acti-
vity through mammalian Toll-like receptors. Science, 2001, 292, 
1544–1547. 
50. Aliprantis, A. O. et al., Cell activation and apoptosis by bacterial lipo-
proteins through toll-like receptor-2. Science, 1999, 285, 736–739. 
51. Means, T. K. et al., Differential effects of a Toll-like receptor 
antagonist on Mycobacterium tuberculosis-induced macrophage 
responses. J Immunol., 2001, 166, 4074–4082. 
52. Noss, E. H., Rai, R. K., Sellati, T. J., Radolf, J. D. B., Golenbock, 
D. T., Boom, W. H. and Harding, C. V., Toll-like receptor 2-
dependent inhibition of macrophage class II MHC expression and 
antigen processing by 19-kDa lipoprotein of Mycobacterium 
tuberculosis. J . Immunol., 2001, 176, 910–918. 
53. Pai, R. K., Convery, M., Hamilton, T. A., Boom, W. H. and Harding, 
C. V., Inhibition of IFN-g-induced class II transactivator expres-
sion by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a 
potential mechanism for immune evasion. J . Immunol., 171, 175–
184. 
54. Wang, T., Lafuse, W. and Zwilling, B. S., Regulation of Toll-like 
receptor 2 expression by macrophages following Mycobacterium 
avium infection. J . Immunol., 2000, 165, 6308–6313. 
55. Reiling, R., Holscher, C., Fehrenbach, A., Kroger, S., Kirsching, 
C. J., Goyert, S. and Ehlers, S., Toll like receptor 2 (TLR2)- and 
TLR4-mediated pathogen recognition in resistance to airborne 
infection with Mycobacterium tuberculosis. J . Immunol., 2002, 
169, 3480–3484. 
56. Cobb, M. H., MAP kinase pathways. Progr. Biophys. Mol. Biol., 
1999, 71, 479–500. 
57. Martin-Blanco, E., p38 MAPK signalling cascades: ancient roles 
and new functions. Bioessays, 2000, 22, 637–645. 
58. Chen, C., Chen, Y. H. and Lin, W. W., Involvement of p38 
mitogen-activated protein kinase in lipopolysaccharide-induced 
iNOS and COX-2 expression in J774 macrophages. Immunology, 
1999, 97, 124–129. 
59. Chan, E. D., Morris, K. R., Belisle, J. T., Hill, P., Remigio, L. K., 
Brennan, P. J. and Riches, D. W., Induction of inducible nitric 
oxide synthase-NO* by lipoarabinomannan of Mycobacterium 
tuberculosis is mediated by MEK1-ERK, MKK7-JNK, and NF-kB 
signaling pathways. Infect. Immun., 2001, 69, 2001–2010. 
60. Reiling, N., Blumenthal, A., Flad, H. D., Ernst, M. and Ehlers, S., 
Mycobacteria-induced TNF-a and IL-10 formation by human 
macrophages is differentially regulated at the level of mitogen-
activated protein kinase activity. J . Immunol., 2001, 167, 3339–
3345. 
61. Bhattacharyya, A., Pathak, S., Kundu, M. and Basu, J., Mitogen-
activated protein kinases regulat  Mycobacterium avium-induced 
tumor necrosis factor-a release from macrophages. FEMS 
Immunol. Med. Microbiol., 2002, 34, 73–80. 
62. Roach, S. K. and Schorej, J. S., Differential regulation of the 
mitogen-activated protein kinases by pathogenic and nonpatho-
genic mycobacteria. Infect. Immun., 2002, 70, 3040–3052. 
63. Tse, H. M., Josephy, S. I., Chan, E. D., Fouts, D. and Cooper, A. 
M., Activation of the mitogen-activated protein kinase signaling 
pathway is instrumental in determining the ability of Mycobacte-
rium avium to grow in murine macrophages. J . Immunol., 2002, 
168, 825–833. 
64. Malik, Z. A., Denning, G. M. and Kusner, D. J., Inhibition of Ca2+ 
signaling by Mycobacterium tuberculosis is a sociated with redu-
ced phagosome-lysosome fusion and increased survival within 
human macrophages. J . Exp. Med., 2000, 191, 287–302. 
65 Mendez-Samperio, P., Plama, J. and Vazquez, A., Roles of intra-
cellular calcium and NF-kB in the Bacillus Calmette-Gu rin-
induced secretion of interleukin-8 from human monocytes. C ll. 
Immunol., 2001, 211, 113–122. 
66. Sugawara, I., Mizuno, S., Yamada, H., Matsumoto, M. and Akira, 
S., Disruption of nuclear factor-interleukin-6, a transcription factor, 
results in severe mycobacterial infection. Am. J . Pathol., 2001, 
158, 361–366. 
67. Jones, B. W., Means, T. K., Heldwein, K. A., Keen, M. A., Holl, 
P. J., Belisel, J. T. and Fenton, M. J., Different Toll-like receptor 
agonists induce distinct macrophage responses. J . Leukoc. Biol., 
2001, 69, 1036–1044. 
68. Fratazzi, C., Arbeit, R. D., Carini, C. and Remold, H. G.,  
Programmed cell death of Mycobacterium avium serovar 4- 
infected human macrophages prevents the mycobacteria from 
spreading and induces mycobacterial growth inhibition by freshly 
added, uninfected macrophages. J . Immunol., 1997, 158, 4320–
4327. 
69. Molloy, A., Laochumroonvorapong, P. and Kaplan, G., Apoptosis, 
but not necrosis, of infected monocytes is coupled with killing of 
intracellular bacillus Calmette-Guerin. J . Exp. Med., 1994, 180, 
1499–1509. 
70. Oddo, M., Renno, T., Attinger, A., Bakker, T., MacDonald, H. R. 
and Meylan, P. R. A., Fas ligand-induced apoptosis of infected 
human macrophages reduces the viability of intracellular My o-
bacterium tuberculosis. J . Immunol., 1998, 160, 5448–5454. 
71. Riendeau, C. J. and Kornfeld, H., THP-1 cell apoptosis in respon e to 
mycobacterial infection. Infect. Immun., 2003, 71, 254–259 
72. Bhattacharyya, A., Pathak, S., Basak, C., Law, S., Kundu, M. and 
Basu, J., Execution of macrophage apoptosis by Mycobacterium 
avium through apoptosis signal-regulating kinase 1/p38 mitogen-
activated protein kinase signaling and caspase 8 activation. J . Biol. 
Chem., 2003, 278, 26517–26525. 
73. Balcewicz-Sablinska, M. K., Keane, J., Kornfeld, H. and Remold, 
H. G., Pathogenic Mycobacterium tuberculosis evades apoptosis 
of host macrophages by release of TNF-R2, resulting in inacti-
vation of TNF-a. J . Immunol., 1998, 161, 2636–2641. 
74. Duan, L., Gan, H., Golan, D. E. and Remold, H. G., Critical role 
of mitochondrial damage in determining outcome of macrophage 
infection with Mycobacterium tuberculosis. J . Immunol., 2002, 
169, 5181–5187. 
75 Clemens, D. L., Lee, B. Y. and Horwitz, M. A., ycobacterium 
tuberculosis and Legionella pneumophila phagosomes exhibit 
arrested maturation despite acquisition of Rab7. Infect Immun., 
2000, 68, 5154–5166. 
76. Sturgill-Koszycki, S., Schaible, U. E. and Russell, D. G., Myco-
bacterium-containing phagosomes are accessible to early endo-
somes and reflect a transitional state in normal phagosome 
biogenesis. EMBO J., 1996, 15, 6960–6968. 
77. Crowle, A. J., Dahl, R., Ross, E. and May, M. H., Evidence that 
vesicles containing living virulent M. tuberculosis or M. avium in 
cultured human macrophages are not acidic. Infe t. Immun., 1991, 
59, 1823–1831. 
78. Sturgill-Koszycki, S. et al., Lack of acidification in Mycobacte-
rium phagosomes produced by exclusion of the vesicular proton-
ATPase. Science, 1994, 263, 678–681. 
79. Via, L. E., Deretic, D., Ulmer, R. J., Hibler, N. S., Huber, L. A. 
and Deretic, V., Arrest of mycobacterial phagosome maturation is 
caused by a block in vesicle fusion between stages controll d by 
rab5 and rab7. J . Biol. Chem., 1997, 272, 13326–13331. 
80. Clemens, D. L., Lee, B. Y. and Horwitz, M. A., Deviant expres-
sion of Rab5 on phagosomes containing the intracellular pathogens 
Mycobacterium tuberculosis and Legionella pneumophila is sso-
ciated with altered phagosomal fate. Infect. Immun., 2000, 68, 
2671–2684. 
81. Beatty, W. L., Rhoades, E. R., Hsu, D. K., Liu, F.-T. and Russell, 
D. G., Association of a macrophage galactoside-binding protein 
SPECIAL SECTION: TUBERCULOSIS 
CURRENT SCIENCE, VOL. 86, NO. 1, 10 JANUARY 2004 110
with Mycobacterium-containing phagosomes. Cell. Microbiol., 
2002, 4, 167–176. 
82. Malik, Z. A., Iyer, S. S. and Kusner, D. J., Mycobacterium tuber-
culosis phagosomes exhibit altered calmodulin-dependent signal 
transduction: contribution to inhibition of phagosome-lys s e 
fusion and intracellular survival in human macrophages. J . 
Immunol., 2001, 166, 3392–3401. 
83. Malik, Z. A., Thompson, C. R., Hashimi, S., Porter, B., Iyer, S. S. 
and Kusner, D. J., Cutting edge: Mycobacterium tuberculosis blocks 
Ca2+ signaling and phagosome maturation in human macrophages 
via specific inhibition of sphingosine kinase. J . Immunol., 2003, 
170, 2811–2815. 
84. Ferrari, G., Langen, H., Naito, M. and Pieters, J., A coat protein 
on phagosomes involved in the intracellular survival of myco-
bacteria. Cell, 1999, 97, 435–447. 
85. Gatfield, J. and Pieters, J., Essential role for cholesterol in entry of 
mycobacteria into macrophages. Science, 2000, 288, 1647–1650. 
86. Russell, D. G., Dant, J. and Sturgill-Koszycki, S., Mycobacterium 
avium- and Mycobacterium tuberculosis-containing vacuoles are 
dynamic, fusion-competent vesicles that are accessible to glyco-
sphingolipids from the host cell plasmalemma. J . I munol., 1996, 
156, 4764–4773. 
87. Pancholi, P., Mirza, A., Bhardwaj, N. and Steinman, R. M., Seque-
stration from immune CD4+ T cells of mycobacteria growing in 
human macrophages. Science, 1993, 260, 984–986. 
88. Wadee, A. A., Kuschke, R. H. and Dooms, T. G., The inhibitory 
effects of Mycobacterium tuberculosis on MHC class II expression 
by monocytes activated with riminophenazines and phagocyte 
stimulants. Clin. Exp. Immunol., 1995, 100, 434–439. 
89. Wojciechowski, C. W., DeSanctis, J., Skamene, E. and Radzioch, 
D., Attenuation of MHC class II expression in macrophages infec-
ted with Mycobacterium bovis bacillus Calmette-Guerin involves 
class II transactivator and epends on the Nramp1 gene. J . 
Immunol., 1999, 163, 2688–2696. 
90. Stenger, S., Niazi, K. R. and Modlin, R. L., Down-regulation of 
CD1 on antigen-presenting cells by infection with Mycobacterium 
tuberculosis. J . Immunol., 1998, 161, 3582–3588. 
91. Noss, E. H., Harding, C. V. and Boom, W. H., Mycobacterium 
tuberculosis inhibits MHC class II antigen processing in murine 
bone marrow macrophages. Cell Immunol., 2000, 201, 63–74. 
92. DeLerma Barbaro, A. et al., Block of Stat-1 activation in macro-
phages phagocytosing bacteria causes reduced transcription of 
CIITA and consequent impaired antigen presentation. Eur. J . 
Immunol., 2002, 32, 1309–1318. 
93. Jiao, X. et al., Dendritic cells are host cells for mycobacteria in 
vivo that trigger innate and acquired immunity. J . Immunol., 2002, 
168, 1294–1301. 
94. Bodnar, K. A., Serbina, N. V. and Flynn, J. L., Fate of Mycobac-
terium tuberculosis within murine dendritic cells. Infect. Immun., 
2001, 69, 800–809. 
95. Schaible, U. E., Agens, K., Fischer, K., Collins, H. L. and 
Kaufmann, S. H., Intersection of group I CD1 molecules and 
mycobacteria in different intracellular compartments of dendritic 
cells. J . Immunol., 2000, 164, 4843–4852. 
96. Greenwell-Wild, T., Vazquez, N., Sim, D., Schito, M., Chatterjee, 
D., Orenstein, J. M. and Wahl, S. M., Mycobacterium avium 
infection and modulation of human macrophage gene expression. 
J . Immunol., 2002, 169, 6286–6297.  
 
 
 
ACKNOWLEDGEMENTS. I thank the Department of Atomic Energy, 
New Delhi, for financial support. I also thank Prof. Parul Chakrabarti 
and Dr Manikuntala Kundu for critically reading the manuscript. 
 
